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The cholesterol sulfotransferase SULT2B1b converts cholesterol to cholesterol sulfate (CS). We 
previously reported that SULT2B1b inhibits hepatic gluconeogenesis by antagonizing the 
gluconeogenic activity of hepatocyte nuclear factor 4 (HNF4). In this study, we showed that the 
SULT2B1b gene is a transcriptional target of HNF4, which led to our hypothesis that the 
induction of SULT2B1b by HNF4 represents a negative feedback to limit the gluconeogenic 
activity of HNF4. Indeed, downregulation of Sult2B1b enhanced the gluconeogenic activity of 
HNF4, which may have been accounted for by the increased acetylation of HNF4 as a result of 
decreased expression of the HNF4 deacetylase sirtuin 1 (Sirt1). The expression of Sult2B1b was 
also induced by HNF4 upon fasting, and the Sult2B1b null (Sult2B1b-/-) mice showed increased 
gluconeogenic gene expression and an elevated fasting glucose level, suggesting that SULT2B1b 
also plays a restrictive role in HNF4 -mediated fasting-responsive gluconeogenesis. We also 
developed thiocholesterol, a hydrolysis-resistant derivative of CS, which showed superior activity 
to that of the native CS in inhibiting gluconeogenesis and improving insulin sensitivity in high-
fat-diet-induced diabetic mice. We conclude that the HNF4 -SULT2B1b-CS axis represents a key 
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endogenous mechanism to prevent uncontrolled gluconeogenesis. Thiocholesterol may be used as 
a therapeutic agent to manage hyperglycemia.  
 
Steroid sulfatase (STS), a desulfating enzyme that converts steroid sulfates to hormonally 
active steroids, plays an important role in the homeostasis of sex hormones. STS is expressed in 
the adipose tissue of both male and female mice, but the role of STS in the development and 
function of adipose tissue remains largely unknown. In this report, we first showed that the adipose 
expression of Sts was induced in the high-fat diet (HFD) and ob/ob models of obesity and type 2 
diabetes. Transgenic overexpression of the human STS in the adipose tissue of male mice 
exacerbated the HFD induced metabolic phenotypes, including increased body weight gain and fat 
mass, and worsened insulin sensitivity, glucose tolerance and energy expenditure, which were 
accounted for by adipocyte hypertrophy, increased adipose inflammation, and dysregulation of 
adipogenesis. The metabolic harm of the STS transgene appeared to have resulted from increased 
androgen activity in the adipose tissue, and castration abolished most of the phenotypes. 
Interestingly, the transgenic effects were sex-specific, because the HFD-fed female STS transgenic 
mice exhibited improved metabolic functions, which were associated with attenuated adipose 
inflammation. The metabolic benefit of the STS transgene in female mice was accounted for by 
increased estrogenic activity in the adipose tissue, whereas such benefit was abolished upon 
ovariectomy. Our results revealed an essential role of the adipose STS in energy homeostasis in 
sex- and sex hormone-dependent manner. The adipose STS may represent a novel therapeutic 
target for the management of obesity and type 2 diabetes.  
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In summary, I have uncovered novel roles and mechanisms of SULT2B1b and STS in 
HNF4 mediated hepatic gluconeonenesis and in estrogen receptor (ER)/ androgen receptor (AR) 
mediated energy homeostasis of adipose tissue respectively, which may facilitate the development 
of novel interventions for metabolic syndromes.  
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 CHAPTER I: NUCLEAR RECEPTORS AND METABOLIC REGULATIONS 
 
Nuclear receptors are a group of ligands binding transcriptional factors. Through regulating 
the expression of target genes, they could regulate physiological processes including reproduction, 
development, and energy metabolism. In the early-1980s, the early several members of steroid 
receptors are first recognized as the sensors and mediators of steroid hormone signaling. The 
subsequent cloning of other nuclear receptor genes based on sequence similarity unexpected 
revealed a large family of nuclear receptor-like genes. There is a total of 48 members discovered 
of transcriptional factor family including the classic endocrine receptors and many so-called 
orphan receptors whose ligands (1 and 2). 
 
Classic nuclear steroid hormone receptors included the glucocorticoid (GR), 
mineralocorticoid (MR), estrogen (ER), androgen (AR), and progesterone (PR) receptors. Steroid 
hormones are synthesized mainly from endogenous endocrine sources that are regulated by 
negative-feedback control of the hypothalamic-pituitary axis. Steroid hormones are circulated in 
the body to their target tissues where they bind to their receptors with high affinity (within nM 
range). Upon hormone binding, steroid receptors bind to DNA as homodimers, and regulate its 
target genes expression. Steroid receptors are well documented to regulate a variety of metabolic 
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and developmental process including sexual differentiation, reproduction, energy metabolism, and 
electrolyte balance (3). 
 
Orphan nuclear receptors include receptors for fatty acids (peroxisome proliferator- 
activated receptors; PPARs), oxysterols (Liver X receptors; LXRs), bile acids (farnesoid X 
receptor; FXR), xenobiotics (pregnane X receptor; PXR and constitutive androstane receptor; 
CAR). The hepatic nuclear receptor (HNF4) is also one member of the orphan nuclear receptor 
family. Generally, these receptors bind their hydrophobic lipid ligands with relatively lower 
affinities within μM range. During the past decades, researchers have uncovered the significant 
physiological roles, including reproductive biology, inflammation, cancer, diabetes, 
cardiovascular disease, and obesity. These receptors functions as sensors to maintain energy 
homeostasis through regulating the transcription of a family of genes involved in energy 
metabolism, storage, transport, and elimination (4).  
. 
My thesis projects mainly focus on the mediated roles of three of these nuclear receptors 
(the orphan nuclear receptor HNF4, and nuclear steroid hormone receptors ER and AR) in energy 
homeostasis and metabolic syndromes.  
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1.1 ROLE OF HNF4 IN GLUCOSE METABOLISM 
The hepatocyte nuclear factor 4 (HNF4) is a liver-enriched orphan nuclear receptor that 
plays a pivotal role in energy homeostasis by regulating the metabolism of glucose and lipids (5, 
6). HNF4 promotes gluconeogenesis through its positive regulation of PEPCK and G6Pase genes 
(7, 8). Although the HNF4-promoted gluconeogenesis is physiologically essential, uncontrolled 
gluconeogenesis is a major pathogenic event in the development of T2D (9–11). The expression 
and activity of HNF4 are elevated in response to fasting, which is essential to maintain the fasting 
glucose level (9). Increased gluconeogenesis is also responsible for the increased whole-body 
glucose production in T2D patients after an overnight fasting (10, 11). The activity of HNF4 can 
be regulated by posttranslational modifications, including acetylation (12). The acetylation 
homeostasis of HNF4 is controlled by both deacetylases, such as sirtuin 1 (Sirt1) (13), and 
acetylates, such as CBP/p300 (14).  
 
 
 
 
 
 
 
 
 4 
1.2 ROLE OF ENDOCRINE NUCLEAR RECEPTORS ER AND AR IN ENERGY 
HOMEOSTASIS 
In addition to reproduction, sex hormones, including estrogens and androgens, are 
implicated in various physiological functions, including energy homeostasis (15 and 16). 
Postmenopausal women have increased risk of developing metabolic syndromes, such as obesity 
and insulin resistance type 2 diabetes. Estrogen replacement therapies ameliorate metabolic 
disorders and decreased abdominal fat gain in women and rodent models (17 and 18). Human 
subjects lacking Estrogen receptor α (ERα) or aromatase, the primary enzyme converting 
androgens to estrogens were found to develop insulin resistance and obesity (19-21). Additionally, 
mice deficient of aromatase were also reported to develop obesity due to reduced physical activity 
and decreased lean body mass (22 and 23). The deficiencies of estrogens also lead to impaired 
insulin sensitivity and adiposity in both aromatase knockout (21) and Erα deficient (22) mice. On 
the other hand, estrogens administration improves insulin sensitivity and adiposity in HFD fed 
female mice (24) and in ob/ob mice (25). In general, estrogen plays a beneficial role to improve 
energy homeostasis in both male and female. The effects of estrogen on fat have been reported, 
while most are accounted on whole body effect of estrogen or certain peripheral tissues like liver 
and brain. The adipose tissue (AT) specific role of estrogen in energy homeostasis is still unclear.  
 
The role of androgen in energy homeostasis has also been studied (26). Unlike estrogen, 
the role of androgen shows sexual dimorphisms. In female, excess androgenic activity in liver, 
skeletal muscle, pancreatic β-cells, and metabolic centers in the hypothalamus synergize to worsen 
metabolic function, inflammation, visceral adiposity, and T2D (26-33). While, in male low 
testosterone predisposes to diabetes and hyperglycemia and low-level testosterone is associated 
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with diabetes (34-36). The tissue specific roles of androgen in central system and several peripheral 
tissues including liver, pancreatic β-cells, and skeletal muscle in male have been established. 
Androgen through activating AR could inhibit hepatic lipogenesis, promote hepatic lipid 
oxidation, improve insulin sensitivity and prevent hepatic steatosis (37- 39). Androgen also 
improved pancreatic β-cell function and increase insulin secretion, which could be important 
implications for prevention of T2D in hypoandrogenic men (40 and 41). Testosterone deficiency 
promotes insulin resistance in skeletal muscle at least partially via an AR- dependent mechanism 
involving a decrease in PGC1a-mediated oxidative and insulin sensitive muscle fibers (42). 
Although, it is known that testosterone deficiency leads to visceral obesity in men and there is an 
inverse correlation between total serum testosterone and the amount of visceral adipose tissue (43 
and 44). This has been reported to be indirectly mediated via AR actions in muscle (45-48). The 
direct effect of androgen on adiposity and AT energy homeostasis is unclear. 
 6 
 CHOLESTEROL SULFOTRANSFERASE (SULT2B1B) AND STEROID 
SULFATASE (STS) IN ENERGY METABOLISM 
 
As mentioned, the nuclear receptors function as sensors to maintain energy homeostasis 
through regulating the transcription of a family of genes involved in energy metabolism, storage, 
transport, and elimination. The biological functions of these “sensors” are highly related to the 
nutrients themselves, and therefore the cross talk between nutrients and nutrient sensors form feed-
back regulations to maintain physical homeostasis. On the other hand, there are classes of 
metabolizing enzymes responsible for the chemical and biological balance of the nutrients, which 
including the Cholesterol Sulfotransferase (SULT2B1b) and the Steroid Sufatase (STS). In my 
thesis study, I dedicated to investigating of the roles of these two nutrients metabolism enzymes 
in energy homeostasis through the mediation of nuclear receptors.  
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2.1 CHOLESTEROL SULFOTRANSFERASE (SULT2B1B) AND ITS 
ENZYMATIC PRODUCTS CHOLESTEROL SULFATE (CS) 
Sulfotransferases (SULTs) catalyze the transfer of a sulfate group from 3- 
phosphoadenosine 5-phosphosulfate (PAPS) to an acceptor molecule (49). Sulfation plays an 
essential role in regulating the chemical and functional homeostasis of endogenous and exogenous 
molecules (50 and 51).  
 
 The mouse SULT2B1 hydroxysteroid sulfotransferase (designated SULT2B1a) has two 
isoforms the SULT2B1b gene and the later cloned SULT2B1a gene. These two isoforms are akin 
with each other, and in fact derived from the same gene as a result of an alternative exon 1 and 
differential splicing. Thus, the two isoforms differ only at their amino termini. The identical gene 
structure of mouse SULT2B1 gene and human SULT2B1 gene indicates that this gene and its 
products are highly conserved within mouse and human. However, the cloned mouse SULT2B1a 
isoform is lightly different from its human counterpart in its gene structure. In comparison to the 
unique amino terminus of human SULT2B1a with only 8 amino acids, mouse SULT2B1a is 54 
amino acids in length. While the lengths of the unique amino terminus for the mouse and human 
SULT2B1b isoforms are quite similar, at 20 and 23 amino acids, respectively. The longer amino 
terminus of mouse SULT2B1a accounts for its being approximately 5% larger than SULT2B1b, 
which is the opposite of the case with the human counterparts, where SULT2B1b is larger than 
SULT2B1a. In addition to the structural distinction between human and mouse SULT2B1a, they 
also differ functionally (52). Mouse SULT2B1a efficiently sulfonates cholesterol with the highest 
kcat/Km ratios, however human SULT2B1a sulfonates cholesterol very weakly (53).  
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Differential expression patterns of SULT2B1a and SULT2B1b in organ systems, 
particularly the skin and brain, in association with their respective substrate preferences reveal 
potential physiological implications for the sulfonated product. SULT2B1b, now recognized as a 
cholesterol sulfotransferase, is quantitatively the predominant hydroxysteroid sulfotransferase 
expressed in human skin. The human fetal brain appears to only express the SULT2B1a isoform 
which is consistent with the evidence that the brain and spinal cord in mouse almost exclusively 
express SULT2B1a (54). SULT2B1b is expressed in multiple tissues, including the liver (54-56). 
Although the mouse liver does not have a high basal expression of SULT2B1b (56), the hepatic 
expression of SULT2B1b is highly inducible, such as in response to TCPOBOP, an agonist for the 
constitutive androstane receptor (CAR) (56).   
 
As mentioned, the primary enzymatic byproduct of SULT2B1b, is Cholesterol sulfate, a 
predominant steroid sulfate in the circulation. Cholesterol sulfate concentrations in human plasma 
range from 134-254 ug/ml (57 and 58). Cholesterol sulfate is also present in various body fluids 
and tissues, including urine, bile, seminal plasma, skin, adrenal, kidney and liver (55 and 59). 
Despite its prevalence and abundance, the physiological role of CS remains to be defined. 
Cholesterol sulfate has been recognized to be essential in skin development as a regulatory 
molecule in human keratinocyte differentiation and creation of the barrier (6 and 70). In vitro 
studies showed CS is a nature agonist for the retinoic acid-related orphan receptor (ROR) (60). It 
was suggested that CS may play a role in immune response and a shortage of CS in fetus may 
contribute to the development of autism (61). Cholesterol sulfate is also a major cell surface 
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substance that is essential for the cell membrane function (62). Previously, Shi published that 
SULT2B1b and CS could inhibit HNF4 mediated gluconeogenesis (6).  
2.2  ROLE OF STEROID SULFOTASE (STS) IN ENERGY HOEMEOSTASIS 
Steroid Sulfatase (STS), also known as aryl sulfatase C, is an enzyme responsible for the 
cleavage of steroid sulfate to active steroid, most important examples are reversing estrone sulfate 
to estrone and dehydroepiandrosterone sulfate (DHEA-S) to DHEA (63). Pregnenolone sulfate and 
cholesterol sulfate are the other two important substrates of STS. Steroids are mostly existing in 
sulfate form, as in the case of DHEA-S, which is present in concentrations up to 100-fold higher 
than unconjugated DHEA (64).  The half-life of steroid sulfate is also relatively long in comparison 
with active steroids. For instance, estrone sulfate is very abundant in human serum with 
concentrations 10–20-fold higher than estrone and estradiol (65). The expression of STS is 
confirmed not only in reproductive organs like the ovaries, placenta, testis, endometrium, but also 
in the adrenal glands, kidney, bone, skin and fat tissue brain, fetal lung, lymphocytes, aorta (66). 
 
Steroid sulfonation and de-conjugation pathways play an important role in steroid chemical 
and biological homeostasis. Steroid sulfatase (STS) converts cholesterol sulfate to cholesterol, 
which is then transported into mitochondria for conversion to pregnenolone, and downstream 
adrenal products including DHEA and DHEA sulfate. DHEA sulfate serves as the precursor 
molecule for synthesis of the non-adrenal steroid hormones, including testosterone and estrogens 
(67-69). Therefore, STS is involved in many physiological and pathophysiological conditions 
based on the biological roles of its substrates. Inactivation of the STS gene results in X-linked 
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ichthyosis due to excess deposition of cholesterol sulfate in the skin (70). As mentioned in 1.2, 
estrogen and androgen dysregulation is always associated with increased risk of obesity, insulin 
resistance, diabetes, or cardiovascular disease (71). STS is the main sulfates to synthesize the 
active sex hormones (estrogens and androgens), the role of STS activity in metabolism is more 
complex and seems to be sex specific. Previously Jiang reported that the beneficial role STS in 
hepatic energy homeostasis in both genders but via distinct mechanisms. The metabolic benefit in 
female transgenic mice specifically expressing STS in the liver was likely mediated by increased 
hepatic estrogen activity, whereas the protective effect of STS in males may have been accounted 
by decreased inflammation in white adipose tissue (72). STS is also expressed in the white adipose 
tissue of women where it plays an important role in the formation of biologically active sex 
hormones, especially in postmenopausal women. Both the expression and activity of STS were 
higher in postmenopausal adipose tissues than in premenopausal adipose tissues, which might 
suggest that the hydrolysis of circulating steroid-S may have played an increasing role after 
menopause in local steroid biosynthesis in the adipose tissue (73).  
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 CHAPTER III: REGULATION OF CHOLESTEROL SULFOTRANSFERASE 
SULT2B1B BY HEPATOCYTE NUCLEAR FACTOR 4 A CONSTITUTES A 
NEGATIVE FEEDBACK CONTROL OF HEPATIC GLUCONEOGENESIS 
 
Hepatic gluconeogenesis and lipogenesis are two critical components of energy 
metabolism. Previous studies have suggested a critical role of SULT2B1b in hepatic energy 
homeostasis. SULT2B1b can inhibit lipogenesis by sulfonating and deactivating oxysterols, the 
endogenous agonists for the lipogenic nuclear receptor liver X receptor (LXR) (51). The 
expression and regulation of Sult2B1b were found to be important for the antilipogenic activity of 
CAR (56). We recently reported that SULT2B1b and its enzymatic by-product CS attenuated 
hepatic gluconeogenesis by inhibiting HNF4 and increased serum leptin level to inhibit obese 
induced metabolic disorder (6). HNF4 has diverse functions, including its regulation of hepatic 
gluconeogenesis by positively regulating the gluconeogenic enzymes phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase). Interestingly, we found that the 
expression of SULT2B1b was positively regulated by HNF4. In this case, SULT2B1b and 
HNF4α may form a negative feedback mechanism to regulate HNF4 mediated gluconeogenesis. 
In this study, our goal is to demonstrate the positive regulation of SULT2B1b by HNF4 and to 
investigate the physiological meaning of this negative feedback regulation in hepatic 
gluconeogenesis.  
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PIC 1 
 
 
Picture 1. Description of the negative feedback regulation between HNF4 and SULT2B1b. 
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3.1  METHOD 
3.1.1 Mice, diet, and chemicals. 
The Sult2B1b-/- mice (strain number 018773) were obtained from the Jackson Laboratory 
(Bar Harbor, ME). Standard chow from PMI Nutrition (St. Louis, MO) or HFD (S3282) from Bio-
serv (Frenchtown, NJ) was used. All chemicals were purchased from Sigma (St. Louis, MO).  
3.1.2 Isolation of mouse and human primary hepatocytes.  
Mouse primary hepatocytes were isolated by collagenase perfusion from 8-week-old male 
wild-type or Sult2B1b-/- mice as we have previously described (6). Human primary hepatocytes, 
also isolated by collagenase perfusion, were obtained through the NIH-sponsored Liver Tissue 
Procurement and Distribution System at the University of Pittsburgh.  
3.1.3 Histological and serum insulin analysis.  
For Oil red O staining, snap-frozen liver tissues were sectioned into 8- m-thick samples and 
stained in 0.5% Oil red O in propylene glycerol. The serum insulin level was measured by an assay 
kit (catalog number 90080) from Crystal Chem (Downers Grove, IL).  
3.1.4  Immunoprecipitation, Western blot analysis, and ChIP assays.  
Immunoprecipitation and Western blot analysis were performed as described previously 
(6). The primary antibody used for HNF4 (catalog number MA1-199) was purchased from 
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ThermoFisher Scientific (Pittsburgh, PA). Anti-acetylated lysine (catalog number 9441S), anti-
Sirt1 (D60E1), and anti-FLAG (catalog number 2368) antibodies were purchased from Cell 
Signaling (Danvers, MA). The anti-Acss (sc-85258) and anti-SULT2B1b (sc-67103) antibodies 
were purchased from Santa Cruz (Santa Cruz, CA). Western blotting images were quantified with 
the ImageJ software (http://rsb.info.nih.gov/ij/). The ChIP assay was performed as we have 
previously described (6).  
3.1.5 Glucose production assay.  
Cells were washed three times with phosphate-buffered saline (PBS) to remove glucose. Cells 
were then incubated in glucose production buffer (glucose-free Dulbecco’s modified Eagle 
medium [DMEM] [pH 7.4] containing 20 mM sodium lactate and 2 mM sodium pyruvate without 
phenol red) for 4 h, after which 500 l of medium was removed and centrifuged at 15,000 g for 10 
min. The glucose content in the supernatant was measured with a glucose assay kit from Sigma. 
Glucose concentrations were normalized to cellular protein concentrations.  
3.1.6 Immunofluorescence. 
Cells were seeded on glass slides, fixed with 4% paraformaldehyde in PBS, and incubated 
overnight with the primary antibody at 4°C. Cells were then incubated with fluorescein- labeled 
goat anti-rabbit IgG and visualized by confocal microscopy.  
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3.1.7   Gene expression analysis.  
RNA was extracted by using the TRIzol reagent from Invitrogen (Carlsbad, CA). Reverse 
transcription into cDNA was performed by using reverse transcriptase Superscript II and oligoDT 
from Invitrogen. Quantitative RT-PCR was performed with an ABI Prism 7000 thermal cycler 
from Applied Biosystems by using the SYBR green detection reagent. Cyclophilin was used as 
the housekeeping control gene.  
3.1.8  GTT and ITT.  
For the glucose tolerance test, mice received an intraperitoneal injection of D-glucose at 2 
g/kg body weight after a 16-h fasting. For the insulin tolerance test, mice received an 
intraperitoneal injection of insulin at 0.5 unit/kg after a 6-h fasting. 
3.1.9 Adenoviral expression vectors.  
  Adenoviruses expressing Hnf4 (Ad-Hnf4), shRNA against Hnf4 (Ad-shHnf4), or -
galactosidase (Ad-shLacZ) were gifts from Yanqiao Zhang from the Northeast Ohio Medical 
University.  
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3.1.10  Cloning of SULT2B1b gene promoters, transient-transfection and reporter gene 
assays, and EMSA.  
      The mouse Sult2B1b gene promoter (nucleotides [nt] 156 to 200) and the human 
SULT2B1b gene promoter (nt 197 to 154) were cloned by PCR using the following primers 
(5= to 3=): Sult2B1b Forward, CGACGCGTCGCGGCAAAACTTGCAAAGTAA; Sult2B1b 
Reverse, GAAGATCTTCTCAGACGAGCTCC ACAGG; SULT2B1b Forward, 
CGACGCGTCGGCCATTTCCCAAATGAGCA; SULT2B1b Reverse, GAAGATCTTC 
GAGGACGAGCAGGGAGCA. The promoter sequences were then cloned into the pGL3-Luc 
reporter gene from Promega (Madison WI). Transient-transfection and luciferase reporter gene 
assays were performed as we have previously described, and the transfection efficiency was 
normalized against the -galactosidase activities from a cotransfected CMX- -galactosidase 
vector (6). EMSA using [32P] dCTP-labeled oligonucleotides and in vitro-translated proteins 
was carried out as we have previously described.  
3.1.11  Stability assay of CS and TC in cells.  
 Primary hepatocytes were seeded onto 12-well plates and treated with vehicle, cholesterol 
sulfate (CS) (5 M), or thiocholesterol (TC) (5 M) for 0, 1, 2, 4, 8, 24, or 48 h. At the end of 
treatment, the medium was removed, 1 ml of methanol was added, and the cells were scraped 
and collected. The cells were sonicated for 15 s, and then 1 ml of dichloromethane was added. 
After vortexing for 1 min, the suspension was centrifuged at 13,600 rpm at 4°C for 20 min. 
The supernatant was transferred to a new tube and dried until analysis. For the detection of CS, 
the dried cellular extracts were reconstituted in 20 l of dichloromethane/methanol (1:1, vol/vol) 
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and diluted with 180 l of water-isopropanol-acetonitrile (2:5:3, vol/vol/vol). After 
centrifugation, 5 l of the supernatant was injected into the Waters ultraperformance liquid 
chromatography and quadrupole time of flight mass spectrometry (UPLC-QTOF MS) system 
for analysis. For the detection of TC, the cellular extracts were reconstituted in 20 l of 
dichloromethane and diluted with 180 l of acetonitrile. After centrifugation, 50 l of the 
supernatant was transferred to a new tube and 150 l of 0.1 M borate buffer (pH 8.0) was added. 
One hundred microliters of 10 mM monobromobimane in acetonitrile was added for 
derivatization. The mixture was gently shaken for 2 h before taking 10 l for the UPLC-QTOF 
MS analysis. Chromatographic separation was performed using an Acquity UPLC BEH C18 
column (2.1 by 50 mm, 1.7 m; Waters Corporation, Milford, MA). For CS detection, the 
mobile phase A (MPA) was 10 mM ammonium acetate in water, and the mobile phase B (MPB) 
was 10 mM ammonium acetate in acetonitrile-water (95:5). The gradient began at 30% MPB 
and was held for 0.5 min, followed by 2.5 min of linear gradient to 95% MPB and holding for 
3 min, and then decreased to 30% MPB for column equilibration. For TC detection, the MPA 
was 0.1% formic acid in water, and the MPB was 0.1% formic acid in acetonitrile. The gradient 
began at 30% MPB and was held for 0.5 min, followed by 2.5 min of linear gradient to 95% 
MPB and holding for 2.5 min, increased to 99% MPB in another 0.1 min, and held for 2.4 min 
and then decreased to 30% MPB for column equilibration. The flow rate of the mobile phase 
was 0.5 ml/min, and the column temperature was maintained at 50°C. The QTOF MS system 
was operated in a negative (for CS detection) or positive (for TC detection) high-resolution 
mode with electrospray ionization. The source and desolvation temperatures were set at 150 
and 500°C, respectively. Nitrogen was applied as the cone gas (50 liters/h) and the desolvation 
gas (800 liters/h). Argon was applied as the collision gas. The capillary and cone voltages were 
 18 
set at 0.8 kV and 40 V, respectively. QTOF MS was calibrated with sodium format and 
monitored by the intermittent injection of lock mass leucine encephalin (m/z 556.2771) in real 
time.  
3.1.12   Statistical analysis.  
Data are expressed as the means standard deviations (SD). One-way analysis of variance 
(ANOVA) Tukey’s test or an unpaired Student t test was performed for statistical analysis using 
GraphPad Prism (San Diego, CA). P values of less than 0.05 were considered statistically 
significant.  
3.1.13   Study approval.  
The Central Animal Facility of the University of Pittsburgh is fully accredited by the 
American Association for Laboratory Animal Care (AALAC). All procedures were performed in 
accordance with relevant federal guidelines and with the approval of the University of Pittsburgh 
ethical committee.  
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3.2 RESULTS 
3.2.1 HNF4 positively regulates the expression of Sult2B1b in mouse primary 
hepatocytes and in mouse liver. 
We have previously reported that SULT2B1b can negatively regulate the activity of 
HNF4 (6). To our surprise, we found that the expression of SULT2B1b was positively regulated 
by HNF4 . In the gain-of-function models, infection of primary mouse hepatocytes with 
adenovirus expressing Hnf4  (Ad-Hnf4 ) resulted in the mRNA induction of Sult2B1b, as well 
as the known HNF4 target genes G6pase and Pepck (Fig. 1A). The overexpression of Hnf4 and 
induction Sult2B1b were verified at the protein level by Western blotting (Fig. 1B). In a pharma- 
cological gain-of-function model, treatment of primary hepatocytes with linoleic acid, an 
endogenous Hnf4 activator (74), induced the expression of Sult2B1b, G6pase, and Pepck (Fig. 
1C). The induction of Sult2B1b by linoleic acid was abolished when the expression of Hnf4 was 
downregulated by short hairpin RNA (shRNA) (Fig. 1D). Downregulation of Hnf4 also 
decreased the basal expression of Sult2B1b, G6pase, and Pepck (Fig. 1D). The shRNA knockdown 
of Hnf4 and downregulation of Sult2B1b were verified at the protein level by Western blotting 
(Fig. 1F). In a pharmacological loss-of- function model, treatment of primary mouse hepatocytes 
with BIM5078, an inhibitor of HNF4 (75), downregulated the expression of Sult2B1b, G6pase, 
and Pepck (Fig. 1G). In vivo, hydrodynamic transfection of the mouse liver with the Hnf4 
expression vector increased the hepatic expression of Sult2B1b at both the mRNA (Fig. 1H) and 
the protein (Fig. 1I) levels.  
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Figure 1. HNF4 positively regulates the expression of Sult2B1b in mouse primary 
hepatocytes and in mouse liver.  
(A to G) Experiments were conducted using primary hepatocytes isolated from 8-week-old 
WT male mice. (A) Relative mRNA expression of Hnf4 , Sult2B1b, G6pase, and Pepck in 
hepatocytes infected with adenovirus encoding Hnf4 or the control virus as measured by real-
time PCR. The expression of each gene was arbitrarily set as 1 in hepatocytes infected with the 
control virus. (B) Cells were the same as described for panel A. The protein expression of Hnf4 
and Sult2B1b was measured by Western blotting. (C) Relative mRNA expression of Hnf4, 
Sult2B1b, G6pase, and Pepck in hepatocytes treated with the ethanol control or linoleic acid (25 
M) for 24 h. The expression of each gene was arbitrarily set as 1 in cells treated with ethanol. (D) 
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Hepatocytes were first infected with adenovirus encoding shHnf4 or the control virus for 24 h 
before being treated with ethanol or linoleic acid (25 M) for another 24 h. The expression of 
Sult2B1b was measured by real-time PCR. (E and F) Hepatocytes were first infected with 
adenovirus encoding shHnf4 or the control virus for 24 h, and the gene expression was evaluated 
by real-time PCR (E) and Western blotting (F), respectively. (G) Relative mRNA expression of 
Sult2B1b, G6pase, and Pepck in hepatocytes treated with vehicle (dimethyl sulfoxide [DMSO]) or 
the Hnf4 inhibitor BIM5078 (20 M) for 24 h. (H and I) Eight-week-old WT male mouse livers 
were hydrodynamically transfected with the empty vector or the pCMX-Hnf4 expression 
plasmid. The hepatic expressions of Hnf4 and Sult2B1b mRNA (H) and protein (I) were 
measured by real-time PCR and Western blotting, respectively. Results are expressed as means 
SD from three independent experiments (5 mice per group). *, P 0.05; **, P 0.01; ***, P 0.001.  
 
3.2.2  HNF4 induces the expression of SULT2B1b in human liver cells 
The positive regulation of SULT2B1b by HNF4 is conserved in human liver cells. In the 
human hepatoma HepG2 cells, transfection with the HNF4 expression vector increased the 
expression of SULT2B1b (Fig. 2A). In human primary hepatocytes (HPH), treatment of cells with 
the HNF4 activator linoleic acid induced the expression of both SULT2B1b and G6Pase (Fig. 
2B). In contrast, the basal mRNA expression of SULT2B1b and G6Pase was decreased when the 
expression of HNF4 was knocked down by shRNA (Fig. 2C). The shRNA knockdown of HNF4  
and downregulation of SULT2B1b in human primary hepatocytes were verified at the protein level 
by Western blotting (Fig. 2D). The basal expression levels of SULT2B1b and G6Pase were 
decreased in human primary hepatocytes treated with the HNF4  inhibitor BIM5078 (Fig. 2E). 
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Figure 2 HNF4 induces the expression of SULT2B1b in human liver cells.  
(A) Relative mRNA expression of SULT2B1b in HepG2 cells transfected with the empty 
vector or the Hnf4 -expressing plasmid. The expression of each gene was arbitrarily set as 1 in 
cells transfected with the empty vector. (B) Relative mRNA expression of HNF4, SULT2B1b, 
and G6Pase in human primary hepatocytes (HPH) treated with ethanol or linoleic acid (25 M) for 
24 h. The expression of each gene was arbitrarily set as 1 in cells treated with ethanol. (C) mRNA 
expression of HNF4, SULT2B1b, and G6Pase in HPH infected with adenovirus encoding 
shHNF4 or the control virus. The expression of each gene was arbitrarily set as 1 in cells infected 
with the control virus. (D) Cells were the same as described for panel C. The protein expression 
of HNF4 and SULT2B1b was measured by Western blotting. (E) Relative mRNA expression of 
SULT2B1b and G6Pase in HPH treated with the vehicle (DMSO) or the HNF4 inhibitor 
BIM5078 (20 M) for 24 h. The expression of each gene was arbitrarily set as 1 in cells treated with 
DMSO. Results are expressed as means SD from three independent experiments. *, P 0.05; **, P 
0.01; ***, P 0.001.  
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3.2.3 The mouse and human SULT2B1b genes are transcriptional targets of HNF4. 
The regulation of mouse and human SULT2B1b by HNF4 strongly suggested that the 
SULT2B1b gene is a direct transcriptional target of HNF4 . As a transcriptional factor, HNF4 
often regulates gene expression by binding to the promoter regions of its target genes (76). 
Bioinformatic inspection of the mouse and human SULT2B1b gene promoters revealed a putative 
HNF4 binding site on each of the promoter (Fig. 3A, top panel). The binding of HNF4 to these 
two putative sites was confirmed by electrophoretic mobility shift assay (EMSA) (Fig. 3A, bottom 
panel). The binding was specific in that the binding was efficiently competed by unlabeled wild-
type (WT) binding sites (“self”), but not by their mutant variants. The recruitment of HNF4 to 
the mouse Sult2B1b gene promoter was confirmed by chromatin immunoprecipitation (ChIP) 
assay on mouse primary hepatocytes (Fig. 3B), in which the recruitment of Hnf4 to its known 
binding site in the Pepck gene promoter and a distal region in the Sult2B1b gene promoter were 
included as the positive and negative controls, respectively (Fig. 3B). The recruitment of HNF4 
to the human SULT2B1b gene promoter was confirmed by ChIP assay on human primary 
hepatocytes (Fig. 3C). To determine whether the mouse and human SULT2B1b gene promoters 
can be transactivated by HNF4 and the functional relevance of the HNF4 binding sites, we 
cloned the mouse and human SULT2B1b gene promoters, as well as their mutant variants in which 
the HNF4 binding sites were mutated by site-directed mutagenesis. Both the mouse (Fig. 3D) 
and human (Fig. 3E) SULT2B1b gene promoter luciferase reporter genes were activated by the of 
the HNF4 binding sites, we cloned the mouse and human SULT2B1b gene promoters, as well as 
their mutant variants in which the HNF4 binding sites were mutated by site-directed mutagenesis. 
Both the mouse (Fig. 3D) and human (Fig. 3E) SULT2B1b gene promoter luciferase reporter genes 
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were activated by the cotransfection of HNF4 , but the activation was abolished when the HNF4 
binding sites were mutated.  
 
 
 
 
Figure 3 The mouse and human SULT2B1b genes are transcriptional targets of HNF4.  
(A) Sequences of the predicted HNF4 binding sites in the mouse and human SULT2B1b 
gene promoters and their mutant variants (top). The bindings of HNF4 to the putative HNF4 
binding sites were shown by electrophoretic mobility shift assay (EMSA) (bottom). (B and C) 
ChIP assay showing the recruitment of HNF4 onto the mouse (C) and human (D) SULT2B1b 
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gene promoters. (D and E) Activation of the mouse (D) and human (E) SULT2B1b promoter 
reporter genes by HNF4. Cells were cotransfected with the indicated WT or mutant reporter 
genes, and receptors were monitored by luciferase assay. Results are expressed as means SD from 
three independent experiments. *, P 0.05; **, P 0.01.  
 
3.2.4 Downregulation or ablation of Sult2B1b increases the gluconeogenic activity of 
Hnf4 in mouse primary hepatocytes. 
Having shown that SULT2B1b is an HNF4 target gene and knowing that SULT2B1b can 
inhibit the gluconeogenic activity of HNF4 , we hypothesized that the induction of SULT2B1b 
by HNF4 may represent a negative feedback to limit the gluconeogenic activity of HNF4 . 
Based on this hypothesis, we predicted that downregulation or ablation of SULT2B1b will increase 
the gluconeogenic activity of HNF4 due to the lack of SULT2B1b-mediated inhibition. We first 
tested our hypothesis in vitro using mouse primary hepatocytes. In this experiment, hepatocytes 
were transiently transfected with the Sult2B1b-targeting small interfering RNA (siRNA) or the 
nontargeting control siRNA, in the presence or absence of the cotransfection of HNF4 , followed 
by the measurement of forskolin (FSK)-responsive glucose production and the expression of 
gluconeogenic genes. The knockdown of Sult2B1b (Fig. 4A) and overexpression of Hnf4 (Fig. 
4B) were confirmed by real-time PCR (RT-PCR). As shown in Fig. 4C, knockdown of Sult2B1b 
increased the basal and Hnf4 -responsive glucose production, which was accompanied by 
increased expression of G6pase (Fig. 4D) and Pepck (Fig. 4E). In another independent loss-of-
function model, we infected hepatocytes isolated from the WT and Sult2B1b-/- mice with control 
adenovirus (Ad-Control) or Ad-Hnf4 . The expression of transduced Hnf4 was verified by real-
time PCR (Fig. 4F). Again, increased Hnf4 -responsive glucose production (Fig. 4G) and 
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expression of G6pase (Fig. 4H) and Pepck (Fig. 4I) were observed in Sult2B1b-/- hepatocytes 
compared to what was seen in hepatocytes isolated from the WT mice. 
 
 
Figure 4 Downregulation or ablation of Sult2B1b increases the gluconeogenic activity of 
Hnf4 in mouse primary hepatocytes.  
(A) Hepatocytes isolated from 8-week-old WT male mice were transfected with scrambled 
or Sult2B1b-targeting siRNA for 48 h. The downregulation of Sult2B1b was verified by real-time 
PCR. The expression was arbitrarily set as 1 in cells transfected with scrambled siRNA. (B to E) 
Relative mRNA expression of Hnf4 (B), G6pase (D), and Pepck (E) and glucose production (C) 
in hepatocytes transfected with scrambled or Sult2B1b-targeting siRNA for 24 h followed by 
transfection with the empty vector or the pCMX-Hnf4 -expressing vector for another 24 h. The 
expression of each gene or glucose production was arbitrarily set as 1 in cells transfected with 
scrambled siRNA followed by transfection with the empty vector. (F to I) Relative mRNA 
expression of Hnf4 (F), G6pase (H), and Pepck (I) and glucose production (G) in hepatocytes 
isolated from 8-week-old male WT or Sult2B1b-/- mice infected with adenovirus encoding Hnf4 
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or the control virus. The expression of each gene or glucose production was arbitrarily set as 1 in 
cells isolated from WT mice infected with the control virus. Results are expressed as means SD 
from three independent experiments. *, P 0.05; **, P 0.01; ***, P 0.001.  
 
 
3.2.5 Ablation of Sult2B1b increases the gluconeogenic activity of Hnf4 in vivo, and 
Sult2B1b-/- mice exhibit elevated fasting blood glucose levels.  
To determine the effect of Sult2B1b ablation on Hnf4 activity in vivo, WT and Sult2B1b-
/- mice were hydrodynamically transfected with the empty vector or the Hnf4 expression vector. 
The overexpression of Hnf4 in both genotypes was confirmed by real-time PCR (Fig. 5A). The 
Sult2B1b-/- mice showed increased basal and Hnf4 -responsive expression of G6pase (Fig. 5B) 
and Pepck (Fig. 5C).  
 
Fasting is known to induce the expression and activity of Hnf4 and increase 
gluconeogenesis (9). To determine the effect of Sult2B1b ablation on fasting-responsive 
gluconeogenesis, WT and Sult2B1b-/- mice maintained on a chow diet were fasted for 24 h. As 
shown in Fig. 5D, fasting induced the expression of Hnf4 in both genotypes. The induction of 
Hnf4 in WT mice was accompanied by the induction of Sult2B1b (Fig. 5E), consistent with the 
notion that Sult2B1b is a transcriptional target of Hnf4 . The fasting-responsive induction of 
Hnf4 and Sult2B1b protein expression was verified by Western blotting (Fig. 5F). The fasting-
responsive expression of G6pase (Fig. 5G), but not of Pepck (Fig. 5H), was elevated in Sult2B1b-
/- mice compared to their WT counter- parts. Moreover, the Sult2B1b-/- mice exhibited higher 
levels of fasting glucose (Fig. 5I), which may have been contributed to by the increased 
gluconeogenesis. 
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Figure 5 Ablation of Sult2B1b increases the gluconeogenic activity of Hnf4 in vivo, and 
Sult2B1b-/- mice exhibit elevated fasting blood glucose levels. 
Eight-week-old WT and Sult2B1b-/- male mice were used. (A to C) Relative hepatic 
mRNA expression of Hnf4 (A), G6pase (B), and Pepck (C) in the livers of WT and Sult2B1b-/- 
mice hydrodynamically transfected with the empty vector or the Hnf4 -expressing vector. The 
expression of each gene was arbitrarily set as 1 in mice transfected with the empty vector. (D to 
H) Relative hepatic expressions of Hnf4 (D), Sult2B1b (E), Hnf4 and Sult2B1b (F), G6pase 
(G), and Pepck (H) in fed and fasted WT and Sult2B1b-/- mice were measured by real-time PCR 
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(D, E, G, and H) or Western blotting (F). The expression of each gene was arbitrarily set as 1 in 
fed WT mice. (I) Fasting glucose levels. n 5 mice per group. *, P 0.05; **, P 0.01; ***, P 0.001.  
 
3.2.6 Ablation of Sult2B1b increases the acetylation of Hnf4 by suppressing the Hnf4 
deacetylase Sirt1.  
The transcriptional activity of HNF4 can be regulated by acetylation. Acetylation of 
HNF4 activates HNF4 by promoting its nuclear translocation (6 and 12). We first used 
immunofluorescence to determine whether Sult2B1b ablation impacted the subcellular 
localization of Hnf4 in primary mouse hepatocytes. Indeed, compared to the WT hepatocytes, in 
which Hnf4 was distributed in both the cytoplasm and nucleus, Hnf4 was almost exclusively 
nuclear in hepatocytes isolated from the Sult2B1b-/- mice (Fig. 6A). The effect of Sult2B1b 
ablation on the subcellular distribution of Hnf4 was further confirmed by nuclear-cytosolic 
fractionation of the liver and Western blotting (Fig. 6B). To examine the effect of Sult2B1b 
ablation on the acetylation of Hnf4 , hepatocyte lysates were immunoprecipitated with an anti-
acetyl lysine antibody before immunoblotting with an anti-Hnf4 antibody. As shown in Fig. 6C, 
the acetylation of Hnf4 was increased in hepatocytes isolated from the Sult2B1b-/- mice. The 
increased acetylation of Hnf4 in Sult2B1b-/- mice was associated with a decreased expression of 
Sirt1, a NAD (+)-dependent deacetylase that can deacetylate HNF4 (13) (Fig. 6D), as well as an 
increased expression of acetyl coenzyme A (acetyl-CoA) synthetase (Acss) (Fig. 6E), the enzyme 
that catalyzes the formation of the acetyl donor acetyl-CoA (77). 
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Figure 6 Ablation of Sult2B1b increases the acetylation of Hnf4 by suppressing the Hnf4 
deacetylase Sirt1. Eight-week-old WT and Sult2B1b-/- male mice were used.  
(A) The subcellular distribution of Hnf4 was visualized by immunofluorescence using an 
anti-Hnf4 antibody (red) in primary hepatocytes isolated from WT and Sult2B1b-/- mice. DAPI 
(4=,6-diamidino-2-phenylindole; blue) was used for nuclear counterstaining. (B) Western blot 
analysis of the Hnf4 protein levels in the nuclear and cytoplasmic fractions of WT and Sult2B1b-
/- mouse liver. The purity of the nuclear and cytoplasmic fractions was confirmed by 
immunoblotting with histon-H3 antibody (a nuclear marker) and -tubulin antibody (a cytoplasmic 
marker), respectively. (C) Liver lysates of WT and Sult2B1b-/- mice were immunoprecipitated 
with an anti-acetyl lysine antibody before immunoblotting with an anti-Hnf4 antibody. Shown 
below the blot is the densitometric quantification of the Western blotting results. (D and E) The 
hepatic expression levels of Sirt1 (D) and Acss (E) proteins were measured by Western blotting. 
Shown on the right of (D) or below (E) the blot is the densitometric quantification of the Western 
blotting results. Results are expressed as means SD. *, P 0.05.  
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3.2.7  Thiocholesterol shows an improved intracellular stability and better efficacy in 
inhibiting gluconeogenesis in primary hepatocytes. 
 We previously reported that CS can inhibit Hnf4 -mediated gluconeogenesis, 
which is an integral component of Hnf4 - and Sult2B1b-mediated negative feedback regulation 
of gluconeogenesis. However, CS is readily hydrolyzed by the steroid sulfatase, limiting its utility 
as a therapeutic agent (72). We then synthesized thiocholesterol (TC), a structural analog of CS 
generated by replacing the sulfate with a thiol group that is predicted to be hydrolysis resistant 
(Fig. 7A). We hypothesized that TC may mimic the antigluconeogenic activity of CS but with a 
superior bioavailability due to its resistance to hydrolysis. To compare the intracellular stability of 
TC and CS, mouse primary hepatocytes were treated with 5 M TC or CS, and their intracellular 
concentrations were monitored over a 48-h period. As shown in Fig. 7B, in CS-treated cells, the 
intracellular concentration of CS peaked at 4 h but declined steadily thereafter, reaching a very 
low level after 24 h. In contrast, the intracellular concentration of TC continued rising until 48 h 
after the drug treatment. At the functional level, treatment of mouse primary hepatocytes with 5 
M TC, but not 5 M CS, was effective in reducing FSK-stimulated glucose production (Fig. 7C) 
and inhibiting the expression of G6pase and Pepck (Fig. 7D). CS at 20 M could achieve an 
inhibitory effect similar to that obtained with 5M TC (Fig. 7C and D). A similar pattern of superior 
inhibitory effects of TC on glucose production (Fig. 7E) and gluconeogenic gene expression (Fig. 
7F) was observed in human primary hepatocytes. Thiocholesterol was also more efficient than CS 
in inducing the nuclear exclusion of Hnf4 in mouse primary hepatocytes as shown by 
immunofluorescence (Fig. 7G) and nuclear-cytosolic fractionation of the hepatocytes and Western 
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blotting (Fig. 7H). Neither TC nor CS affected the mRNA expression of Hnf4 in mouse primary 
hepatocytes as measured by real-time (RT) PCR (data not shown).  
 
 
 
 33 
Figure 7 Thiocholesterol (TC) shows an improved intracellular stability and better efficacy 
in inhibiting gluconeogenesis in primary hepatocytes. 
(A) Schematic depiction of the synthesis of TC from cholesteryl chloride. (B) Mouse 
primary hepatocytes isolated from 8-week-old male WT mice were treated with 5 M TC or CS for 
up to 48 h, and the intracellular concentrations of TC and CS were measured by using UPLC-mass 
spectrometry. (C and D) Glucose production (C) and expression of gluconeogenic genes (D) in 
mouse primary hepatocytes treated with the indicated concentrations of drugs for 24 h. Cells were 
treated with 10 M FSK for 2.5 h before the glucose production assay. The expression of each gene 
or glucose production was arbitrarily set as 1 in cells treated with DMSO. (E and F) The designs 
of the experiments were similar to those described for panels C and D, except that human primary 
hepatocytes were used. (G) The subcellular distribution of Hnf4 was visualized by 
immunofluorescence using an anti-Hnf4 antibody (red) in primary hepatocytes isolated from WT 
mice and treated with the indicated concentrations of drugs. DAPI (blue) was used for nuclear 
counterstaining. (H) The subcellular distribution of Hnf4 was measured by nuclear-cytosolic 
fractionation of the hepatocytes and Western blotting. Histon-H3 and glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) are nuclear and cytoplasmic markers, respectively. All four lanes are from 
the same blot, with the dotted lines indicating noncontinuous lanes. Results are expressed as means 
SD. *, P 0.05; **, P 0.01. 
3.2.8 Thiocholesterol exhibits a superior activity in reducing fasting blood glucose level 
and improving overall glucose homeostasis in HFD-fed mice. 
 We have previously reported that treatment of HFD-fed mice with CS can inhibit 
gluconeogenesis and improve insulin sensitivity (6). We then used the same HFD model to 
determine whether TC was more efficacious than CS in improving the overall glucose 
homeostasis. Mice were fed with HFD for 12 weeks before receiving intraperitoneal (i.p.) doses 
of TC or CS at 25 mg/kg of body weight 3 times per week for 2 weeks. At 24 h after the last dose 
of drug treatment, TC was more effective than CS in lowering the fasting blood glucose level (Fig. 
8A). At 48 h after the last drug dose, TC remained effective in reducing the fasting blood glucose 
level, but CS was no longer effective (Fig. 8A). Thiocholesterol was also more effective than CS 
in reducing the gluconeogenic (Fig. 8B) and lipogenic (Fig. 8C) gene expression levels. Treatment 
with TC was more effective in improving the animal’s performance in the glucose tolerance test 
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(GTT) (Fig. 8D) and insulin tolerance test (ITT) (Fig. 8E), attenuating HFD-induced hepatic 
steatosis as shown by Oil red O staining (Fig. 8F) and lowering the serum triglyceride and 
cholesterol levels (Fig. 8G) without affecting the plasma insulin levels (data not shown). Treatment 
with TC was also effective in inducing the protein expression of Sirt1 (Fig. 8H) and suppressing 
the protein expression of Acss (Fig. 8I). This regimen of TC or CS was not toxic to the mice, 
because they did not elevate the activities of ALT and AST, nor did they affect the animal’s food 
intake and body weight (data not shown). Treatment with TC or CS had little effect on the hepatic 
mRNA expression of Hnf4 in vivo (data not shown).  
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Figure 8 Thiocholesterol exhibits a superior activity in reducing fasting blood glucose level 
and improving overall glucose homeostasis in HFD-fed mice.  
Six-week-old WT C56BL/6 male mice were fed a high-fat diet (HFD) for 12 weeks 
followed by i.p. injections of vehicle (DMSO), TC (25 mg/kg), or CS (25 mg/kg) 3 times per week 
for 2 weeks while the mice remained on HFD. (A) Fasting blood glucose levels 24 h or 48 h after 
the last dose of drugs. Mice were fasted for 6 h before the blood glucose tests. (B and C) Hepatic 
expression of gluconeogenic genes (B) and lipogenic genes (C) 3 days after the last dose of drugs 
was measured by real-time PCR. The expression of each gene was arbitrarily set as 1 in mice 
treated with DMSO. (D and E) Shown on the right of each panel are the quantifications of GTT 
(D) and ITT (E) presented as areas under the curve (AUC). (F and G) Oil red O staining of the 
liver sections (F) and serum triglyceride and cholesterol levels (G). (H and I) Hepatic expression 
levels of the Sirt1 (H) and Acss (I) proteins was measured by Western blotting. Shown on the right 
are the densitometric quantifications of the Western blotting. Results are expressed as means SD 
from three independent experiments (5 mice per group). *, P 0.05; **, P 0.01; ***, P 0.001.  
3.3 DISCUSSION 
SULT2B1b catalyzes the sulfoconjugation of cholesterol to synthesize CS. We have 
previously shown that the expression of SULT2B1b in the liver was induced in diabetic obese 
mice and during the fasting-to-fed transition. We went on to show that SULT2B1b and CS 
inhibited gluconeogenesis by targeting HNF4 in both cell cultures and transgenic mice (6). These 
results suggested that the induction of SULT2B1b may represent a protective response to 
metabolic stresses.  
 
Knowing that SULT2B1b is a negative regulator of HNF4, it was interesting and 
intriguing to find that SULT2B1b itself is a transcriptional target of HNF4. HNF4 is a 
transcriptional factor of diverse functions, including its gluconeogenic activity by regulating the 
key gluconeogenic enzymes. Although hepatic gluconeogenesis is an essential cellular function, 
uncontrolled gluconeogenesis can be pathogenic, including the development of T2D (7–11). 
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Indeed, genetic variants of HNF4 have been associated with an increased risk of T2D and 
metabolic syndrome in humans (78 and 79). Therefore, it is necessary to have a cellular mechanism 
to limit gluconeogenesis, including that mediated by HNF4. Based on our results, we propose 
that the positive regulation of SULT2B1b by HNF4 represents an effective cellular mechanism 
to keep the HNF4-mediated gluconeogenesis in check, including in the context of fasting 
response. 
 
Consistent with our hypothesis, knockdown or knockout of Sult2B1b enhanced the 
gluconeogenic activity of HNF4, which was associated with increased acetylation and nuclear 
enrichment of HNF4. The increased acetylation of HNF4 may have accounted for the nuclear 
enrichment of HNF4, because acetylation prevents the active export of HNF4 to the cytoplasm 
and increases the DNA binding of HNF4 (12, 14). The increased acetylation of HNF4 in 
Sult2B1b-/- hepatocytes may be explained by the combined effects of a decreased expression of 
the HNF4 deacetylase Sirt1 and an increased expression of the acetyl-CoA-generating enzyme 
Acss. The mechanisms by which Sirt 1 and Acss are regulated by Sult2B1b remain to be 
understood. CBP/p300 has been shown to acetylate HNF4 (14), but the expression of CBP/p300 
was not affected in the Sult2B1b-/- hepatocytes (data not shown).  
 
In addition to inhibiting gluconeogenesis, SULT2B1b has been reported to have  many 
other functions in different cell types and tissues, ranging from inhibiting lipogenesis to promoting 
the liver cell proliferation (80), affecting prostate and colorectal cancer cells (81), and inhibiting 
the T cell receptor signaling (82). It remains to be determined whether HNF4, as a positive 
regulator of SULT2B1b, is also involved in these additional functions of SULT2B1b. Meanwhile, 
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HNF4 is a transcriptional factor that has numerous functions beyond promoting gluconeogenesis 
(83). It would be interesting to know whether and how SULT2B1b, as an HNF4 target gene, may 
have contributed to other cellular functions of HNF4.  
 
Dysregulated gluconeogenesis is primarily responsible for the increased hepatic glucose 
production in T2D (11), suggesting that targeting the gluconeogenic pathway could attenuate 
hyperglycemia. Indeed, metformin, one of the most prescribed drugs for T2D, is believed to exert 
its therapeutic benefit by reducing hepatic gluconeogenesis (84). Based on our findings, it is 
tempting to explore CS as a potential therapeutic agent to manage metabolic disorders, because it 
is a key component in the HNF4 - SULT2B1b negative feedback regulation of gluconeogenesis. 
However, the natural CS is chemically unstable, because it is readily hydrolyzed by the steroid 
sulfatase. In addressing the chemical instability of CS, we have developed and characterized TC, 
a hydrolysis-resistant derivative of CS. Our results showed that TC was superior to CS in inhibiting 
gluconeogenesis and improving overall glucose homeostasis in diabetic mice, which was attributed 
to the increased stability and bioavailability of TC. Certain cholesterol derivatives such as 
oxysterols have been shown to activate LXR, but neither TC nor CS affected the activity of LXR 
in reporter gene assays (data not shown).  
 
In summary, we have identified the cholesterol sulfotransferase SULT2B1b as a novel 
transcript target of HNF4. The induction of SULT2B1b by HNF4 constitutes a negative 
feedback mechanism to prevent uncontrolled gluconeogenesis in diabetes or fasting response. As 
a structural and functional analog of CS, the hydrolysis-resistant TC may be further explored as a 
therapeutic agent to inhibit gluconeogenesis and manage hyperglycemia (PIC. 2).  
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Picture 2 Scaffold of negative feedback regulation between HNF4 and SULT2B1b and its 
enzymatic product CS and derivative TC to regulate hepatic gluconeogenesis. 
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 CHAPTER IV: ADIPOSE TISSUE- AND SEX-SPECIFIC ROLE OF STEROID 
SULFATASE IN EBERGY HOMEOSTASIS  
 
As sex hormones, both androgens and estrogens play important role in energy homeostasis. 
More importantly, these two steroid hormones have sex-specific effects. Although the general 
roles of androgens and estrogens in metabolic syndromes or energy metabolism have been 
investigated, but the fat tissue specific role of these two hormones are still not clear.  
 
The main function of adipose tissue is to store fat and adipose tissue research focused for 
many years on biochemical characterization how fat synthesis and breakdown through lipogenesis 
and lipolysis are regulated (85). In recent research, adipose tissue was demonstrated as the main 
tissue for sex steroid metabolism (86) and production of adipokines, an endocrine factor that is 
negatively correlated with obesity in rodents it became clear that adipose tissue is a highly active 
endocrine organ (87-89). The dysfunction of adipose tissue initiates the development of obesity 
and other metabolic disorders (87-90). AT dysfunction is characterized by predominantly visceral 
fat accumulation (86), changes of beneficial adipokines secretion, increased number of AT 
infiltrating immune cells, enlarged adipocytes, as well as changes in AT mRNA and protein 
expression patterns (89, 91 and 92).   
 
STS catalyzes the sulfation of steroid sulfates to produce active steroids (estrogens and 
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androgens), and it tightly regulates the biological homeostasis of the steroid hormones. Previously, 
our group published the liver specific beneficial role of STS in energy metabolism. Specifically, 
the beneficial role of STS in obese female mice was through estrogen signaling.  In this study, I 
represented the first attempt to comprehensively dissect the sex- and tissue- specific role of STS 
in energy homeostasis in AT. Our results showed that overexpression of STS decreased AT derived 
adiponectin secretion, suppressed adipogenesis, increased fat accumulation and aggravated HFD 
induced diabetic phenotype in males though increasing AT androgenic activity. While, STS 
overexpression in female AT presented the opposite phenotypes via increased estrogen signaling. 
Results from this study may establish STS as a potential therapeutic target to manage metabolic 
diseases, like type 2 diabetes and obesity.  
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4.1 METHOD 
4.1.1 Generation of STS transgenic mice, diet and drug treatment, body composition 
analysis, and indirect calorimetry.  
The human STS cDNA was cloned into the TRE-SV40 transgene cassette (93) to construct 
the TRE-STS transgene. Transgenic production was performed at University of Pittsburgh 
Transgenic Core Facility. The TRE- STS/ aP2-tTA double transgenic which is termed as aP2-STS 
mice were generated by cross-breeding the TRE-STS mice with the aP2-tTA mice (94) and 
maintained in the C57BL/6J background. The TRE-STS line expresses STS under the control of 
the tetracycline response element (TRE). The aP2-tTA line expresses the tetracycline 
transactivator (tTA) in the adipose tissue. In the double transgenic mice, the tTA protein binds to 
TRE and initiates the expression of the transgenic STS.  Administration of doxycycline (DOX, 
2mg/ml) was given in drinking water one week before HFD treatment until the end of experiments. 
HFD (Cat # S3282) with 60% of total calories coming from animal fat was purchased from Bio-
serv (Frenchtown, NJ). Body composition by EchoMRI and indirect calorimetry by Oxymax 
Indirect Calorimetry System were performed as we have previously described (95). The use of 
mice in this study has complied with relevant federal guidelines and institutional policies. 
4.1.2 Western Blot.  
Protein samples will be isolated using RIPA buffer and resolved by electrophoresis on 10% 
SDS-polyacryl- amide gels. Follow by transferring of proteins to polyvinylidene difluoride 
(PVDF) membranes; the membranes were probed with primary antibodies against STS (cat# 
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ab62219) from Abcam (Cambridge, MA). Detection was achieved by using an ECL system from 
Amersham (Piscataway, NJ). 
4.1.3 STS enzymatic activity. 
 Liver or adipose tissue was minced with scissors in ice-cold 0.25M Tris-HCl buffer, pH 
7.5, (1:10 w:v for adipose tissue; 1:20 w/v for liver) and homogenized with a Tissue Tearor 
(BioSpec) using three 30 sec bursts. Protein concentrations of the homogenates were determined 
using a Pierce BCA assay (ThermoFisher).3H-estrone sulfate (53 Ci/mmol; Perkin Elmer-NEN) 
was diluted in 50mM Tris-HCl buffer and 100 µl (140,000 dpm) were added to all assay tubes. 
Radioinert estrone sulfate (Sigma) was dissolved in ethanol and then diluted into 50mM Tris-HCl 
buffer and 100 µl was added to achieve a final concentration of 10µM. Experimental compounds 
were dissolved in ethanol and then diluted in 50mM Tris-HCl buffer. The assay tubes containing 
steroids were preincubated for 5 min at 37˚ C in a water bath. The assay was initiated by addition 
of homogenates (300µl) to the tubes. Control samples (background) received 300µl of buffer in 
place of homogenates. After 30min of incubation at 37˚ C, 3 ml of toluene was added to the tubes. 
The tubes were vortexed for 1min and centrifuged at 1500xg for 10min. Two 500µl aliquots of the 
organic phase were removed from each sample and added to 4ml of scintillation cocktail (Ultima 
Gold, Perkin Elmer) in scintillation vials. Vials were placed in a Packard Tri-Carb scintillation 
counter for determination of product formation, with 50% efficiency for 3H. Each sample was run 
in duplicate. 
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4.1.4 Serum and liver tissue chemistry.  
Serum levels of triglycerides (Cat # 2100-430 from Stanbio), cholesterol (Cat # 1010-430 
from Stanbio), and insulin (Cat # 90080 from Crystal Chem) were measured using commercial 
assay kits. The liver concentration of Acetyl-CoA was measured using the PicoProbe Acetyl CoA 
Assay kit (ab87546) from Abcam (Cambridge, MA).  
4.1.5 Gene expression analysis.  
RNA was extracted by using the Trizol Reagent (Invitrogen). One microgram of RNA from 
each sample was reverse transcribed into cDNA using reverse transcriptase (Superscript II, 
Invitrogen) and oligoDT (Invitrogen). Quantitative RT-PCR was performed with an ABI Prism 
7000 Thermal Cycler (Applied Biosystems) using SYBR Green detection reagent. GAPDH was 
used as the housekeeping control gene. Relative gene expression was calculated using the ΔΔCT 
method, where fold difference was calculated using the expression 2−ΔΔCt. 
4.1.6 Glucose tolerance test (GTT) and insulin tolerance test (ITT). 
 For GTT, mice received an intraperitoneal injection of D-glucose at 2 g/kg body weight 
after a 12-h fasting. For ITT, mice received an intraperitoneal injection of insulin at 0.5 units/kg 
body weight after a 6-h fasting. 
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4.1.7 Histology Study.  
Tissues were fixed in 4% formaldehyde, embedded in paraffin, sectioned at 5 μm, and 
stained with hematoxylin-eosin (H-E) (19). For immunofluorescence, tissue sections were 
deparaffinized and rehydrated, followed by preincubated in blocking buffer (13 PBS, 5% normal 
donkey serum, and 0.3% Triton X-100) for 60 min. Tissue sections were then incubated with 
diluted primary antibody overnight at 4°C and fluorochrome-conjugated secondary antibody for 1 
to 2 h at room temperature in dark the next day. Antibodies used include goat anti-mouse CD68 
(M-20) polyclonal antibody (catalog number sc-7084; Santa Cruz Biotechnology). 
Histomorphometric analysis on insulin-stained pancreatic sections was per- formed using ImageJ 
from the National Institutes of Health (Bethesda, MD), and the percent of islet area per total 
pancreatic area was calculated (20). b-cell mass was determined by multiplying the percentage of 
islet area per pancreatic area by the pancreatic weight. Pancreatic b-cell proliferation and apoptosis 
were determined on insulin-stained pancreatic sections by Ki67 immunostaining (Ki67 antibody 
clone SP6; Neomarkers) and terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL) assay from Promega (Madison, WI), respectively. 
4.1.8 UPLC-MS/MS analysis of adipose tissue estrogens and estrogen sulfates.  
UPLC/MS-MS were carried out with a Waters Acquity UPLC system connected with the 
Xevo TQ triple quadrupole mass spectrometer as we have previously described (96). 
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4.1.9 Statistical analysis.  
Data are expressed as the means ± standard deviations (SD). One-way analysis of variance 
(ANOVA) Tukey’s test was performed for statistical analysis using GraphPad Prism (San Diego, 
CA). P values of less than 0.05 were considered statistically significant. 
4.1.10 Study approval.  
The Central Animal Facility of the University of Pittsburgh is fully accredited by the 
American Association for Laboratory Animal Care (AALAC). All procedures were performed in 
accordance with relevant federal guidelines and with the approval of the University of Pittsburgh 
ethical committee. 
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4.2 RESULTS 
4.2.1 The adipose expression of STS was induced in obese mice, and the creation of 
transgenic mice expressing STS in adipose tissue. 
High-fat diet (HFD) feeing is commonly used mouse model of obesity and type 
2diabetes.We found the expression of endogenous Sts was induced in the epididymal white 
adipose tissue (epi-WAT) of after challenging mice with HFD (Fig. 9A), indicating the possibility 
of sex-specific role of STS in AT energy homeostasis. To understand the functional relevance of 
STS induction and to determine the metabolic effect of STS in vivo, we generated tetracycline-
inducible STS transgenic (Tg) mice expression human STS in the adipose tissue (Fig. 9B). The 
Tet-off transgenic system was composed of two transgenic lines with one line (TetRE-STS) 
expressing hemagglutinin (HA)-tagged STS (HA-STS) under the control of a minimal 
cytomegalovirus promoter (pCMV) fused to the tetracycline-responsive element (TetRE), and the 
other line (aP2-tTA) expressing the tetracycline-transcriptional activator (tTA) in the adipose 
tissue under the control of the aP2 gene promoter. In mice carrying both transgenes (aP2-STS), 
tTA would bind to TetRE and induce the expression of STS, whereas treatment with doxycycline 
(DOX) would dissociate tTA from TetRE and thus silence the expression of STS. The expression 
of the transgenic STS and its silencing by DOX in the adipose tissue tissue was confirmed by RT-
PCR and Western blotting (Fig. 9C). The transgene was undeteactable in non-targeting tissues, 
including the liver and skeletal muscle (data not shown). The adipose expression of the transgene 
was also confirmed at the enzymatic level by using the tritium-labeled estrone sulfate as substrate 
(Fig. 9D). It was noted that the adipose expression of the transgene was comparable between the 
male and female Tg mice (Fig. 9E). 
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Figure 9 The AT expression of STS was induced in obese mice, and creation of transgenic 
mice expressing STS in AT. 
 (A) The mRNA expression of mouse Sts in the epididymal white adipose tissue (Epi-
WAT) of chow-fed Wt mice, high-fat diet (HFD)-fed wild-type (Wt) mice, and chow-fed ob/ob 
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mice. (B) The schematic representation of the Tet-off STS transgenic system. aP2, fatty acid 
binding protein 4; tTA, tetracycline transcriptional activator; SV40 polyA, simian virus 40 
polyadenylation signal; TRE, tetracycline response element; Pmin, minimal human 
cytomegalovirus promoter. (C) The expression of STS protein in the WAT and brown adipose 
tissue (BAT) of the Wt and transgenic (Tg) mice was measured by Western blotting. (D) The 
adipose STS enzymatic activity was determined by estrone sulfate conversion assay and was 
normalized against protein concentrations. (E) The adipose expression of the STS transgene in 
female and male Tg mice was measured by real-time PCR. n=4 mice per group. * or #, P<0.05; 
** or ##, P<0.01; ***, P<0.001, compared to Chow of the sex (A), or compared to the Wt (D). 
 
4.2.2 AT over-expression of STS aggravated HFD-induced adiposity, insulin    resistance, 
and glucose intolerance in male mice. 
When challenged with HFD for 20 weeks, male, but not female, aP2-STS Tg (AS) male 
mice showed significant increase in body weight compared with age-matched WT littermates (Fig. 
10A). Body composition analysis by magnetic resonance imaging revealed that the gain of body 
weight in AS males was largely accounted for by the increase of fat mass, while lean mass was not 
affected (Fig. 10A). Specifically, it was the mass of epi-WAT of AS male but no other AT showed 
significant increase (Fig. 10B). The body weight gain was achieved without significant changes in 
food intake (Fig. 10C). Visceral adipose tissue (mainly epi-WAT) mass correlates with 
development of insulin resistance, while total or subcutaneous adipose tissue mass does not (98). 
It has been thoroughly confirmed that the adipocytes of visceral fat tissue are more lipolytically 
active than subcutaneous adipocytes and thus contribute more to the plasma free fatty acid levels 
(97). This is also consistent with the phenotype observed in HFD challenged AS mice, thus in our 
study we mainly focused on epi-WAT. Metabolic cage analysis showed the oxygen consumption 
and energy expenditure was significantly decreased in HFD-fed AS males (Fig. 10D). When the 
whole-body insulin sensitivity was evaluated, we found that the AS males showed fasting 
 49 
hyperglycemia and worse performance in Glucose Tolerance Test (GTT) and Insulin Tolerance 
Test (ITT) (Fig. 10E and F). To directly assess the insulin sensitivity in AT, we harvested and 
assessed AT tissues for the phosphorylation of Akt (protein kinase B) by Western blotting. 
Decreased Akt phosphorylation was observed in WAT, but not in the liver and skeletal muscle, 
suggesting a WAT-specific of insulin resistance (Fig. 10G). Histological analysis of pancreatic 
sections showed no difference in islet size and total islet area, in HFD challenged AS males and 
WT littermates. This could suggest it was not the alterations in b-cell proliferation and/or death in 
AS males that worsened the whole-body insulin resistance (Fig. 10K). The AS males also showed 
increased serum level of triglycerides, decreased serum level of free fatty acid, but the serum 
cholesterol level was not affected (Fig. 10 I, J and K).  
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Figure 10 AT over-expression of STS aggravated HFD-induced adiposity, insulin 
resistance, and glucose intolerance in male mice. 
All mice are males. Mice were fed with HFD for 20 weeks before analysis. (A-F) Mice 
were analyzed for body weight and body composition (A), fat mass (B), food intake (C), oxygen 
consumption (D), GTT (E) and ITT (F). The quantifications of the GTT and ITT results are shown 
as the areas under the curve. (G) Western blot analysis of Akt phosphorylation in epi-WAT. Shown 
below is the densitometric quantification of the Western blotting results. (H-J) The serum levels 
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of triglycerides (H), free fatty acids (I), and total cholesterol (J). Results are expressed as mean ± 
SD. n=4 mice per group. *, P<0.05; **, P<0.01, compared to the Wt. 
 
 
4.2.3 AT over-expression of STS decreased adipogenesis and lipolysis and aggravated 
HFD- induced adipose and systemic inflammation in males. 
When the gene expression in epi-WAT was profiled, the Tg male showed a decreased 
expression of two key lipolytic lipases, hormone sensitive lipase (Hsl) and adipose triglyceride 
lipase (Atgl) (Fig. 11A). The epi-WAT expression of Lipoprotein lipase (LPL) was also reduced 
in Tg male mice, an enzyme that hydrolyses meal-derived triglycerides in chylomicrons and very 
low-density lipoprotein triglyceride at the capillary endothelium, which regulates the major path 
way of free fatty acid uptake (99) (Fig. 11C). This was consistent with the increased epi-WAT fat 
mass and reduced level of serum free fatty acids (Fig.10B and Fig. 10I). Additionally, the 
expression of the glucose uptake transporter Glut4 and uncoupling protein 1 (UCP1) responsible 
for energy expenditure was downregulated in the epi-WAT of the Tg males (Fig. 11B). There were 
no changes in the expression of lipogenic genes, but the expression adipogenic genes or genes 
indicative of adipogenesis was significantly decreased in the epi-WAT of Tg males (Fig. 11C). 
The down-regulation of peroxisome proliferator activated receptor γ (PPARγ) and phosphorylated 
Erk was confirmed by Western blotting (Fig. 11D). PPARγ is a master regulator of adipogenesis 
(100, 101), whereas the activation of Erk1/2 is required for the cell proliferation in the early phase 
of adipogenesis. Consistent with the inhibition of adipogenesis (102,103). We then went on to test 
the adipocyte secreted adipokine levels. The epi-WAT expression of the beneficial adipokine 
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adiponectin was decreased in the Tg males (Fig. 11E), which may have contributed to the worse 
metabolic function in Tg males. 
 
Obesity is commonly associated with chronic and low-grade inflammation primarily 
originated from the excess of adipose tissue, which often leads to elevated circulating levels of 
proinflammatory cytokines such as Il-6 and Tnfα (103). We then analyzed the epi-WAT local and 
systemic inflammation to determine whether the transgene aggravated fat tissue inflammation and 
contributed to obesity-associated insulin resistance in the males. Immunostaining of Cd68, a 
macrophage marker gene, showed that the epi-WAT of Tg males had a substantially increased 
number and size of the crown-like structures compared with the Wt males (Fig. 11F). Both the 
serum level of Il-6 (Fig. 11G) and adipose expression of pro-inflammatory marker genes (Fig. 
11H) were elevated in Tg males. The average size of adipocytes in the epi-WAT of the Tg males 
was larger than that of the Wt mice (Fig. 11I). It is known that the increase of cytokine level with 
diet induced obesity positively correlates with adipocyte size (103). The adipose hypertrophy may 
contribute to the bigger Ep1-WAT fat pad and decreased lipolysis (Fig. 10A and 10B).  
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Figure 11 AT over-expression of STS decreased adipogenesis and lipolysis and   aggravated 
HFD- induced adipose and systemic inflammation in males. 
 Mice are the same as described in Fig. 10. (A-C) The epi-WAT expression of genes 
responsible for lipolysis (A), glucose uptake and energy expenditure (B), lipogenesis and 
adipogenesis (C) was measured by real-time PCR. (D) The protein level of PPARγ and ERK1/2 
was measured by Western blotting. (E) The The epi-WAT expression of adiponectin. (F) 
Immunostaining of Cd68. Shown on the right is the quantification. (G and H) The serum level of 
IL-6 (G) and adipose expression on pro-inflammatory genes and macrophage marker genes (H). 
Results are expressed as mean ± SD. n=4 mice per group. *, P< 0.05; **, P<0.01; ***, P<0.005, 
compared to the Wt. 
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4.2.4 The adverse effects of STS AT overexpression in male mice were mediated through 
androgen pathway. 
Since the primary function of STS is to de-sulfonate and re-activate estrogens and 
androgens, and estrogens and androgens are known to regulate the metabolic functions of in 
rodents and humans (1, 2), we went on to determine whether the aggravation of metabolic function 
in the Tg males was due to increased estrogenic or androgenic activity in the adipose tissue. In 
HFD-fed, adipose expression of a panel of estrogen responsive genes was not different between 
the Wt and Tg males (Fig. 12A), which was consistent with the unchanged adipose concentrations 
of estrone and estradiol in the Tg males (Fig. 12B). When the androgen activity in the epi-WAT 
was measured, we found the expression of genes that are positively regulated by androgens, such 
as Eefia2 and Mylk (104), were increased in Tg males, whereas the expression of genes known to 
be suppressed by androgens, such as Cebpd, Apoc2 and Mtl (60), were significantly decreased in 
Tg males (Fig. 12C). Consistent with the pattern of gene regulation, the tissue level of testosterone 
in the epi-WAT, but not the liver, was elevated in the Tg males (Fig. 12D), but the circulating level 
of testosterone was not affected (Fig. 12E). The gene regulation was adipose specific, because the 
expression of androgen responsive genes was not affected in the liver and skeletal muscle of the 
Tg males (Fig. L and M). 
 
To further evaluate whether the transgenic phenotype was androgen dependent, we 
performed castration on 4-week-old males to remove the primary source of androgen. The 
castrated mice were then challenged with HFD for 20 weeks. Castration had little effect on the 
expression of the transgene (data not shown), but it abolished the transgenic phenotypes in body 
weight gain and fat mass gain (Fig. 12F), oxygen consumption (Fig. 12G), GTT and ITT (Fig. 
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12H), adipose inflammation at the histological (Fig. 12I) and inflammatory gene expression (Fig. 
4J) levels. The regulation of androgen responsive genes was normalized upon castration as 
expected (Fig. 12K). These results suggested that the adverse metabolic effects in male STS mice 
were estrogen- dependent. 
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Figure 12 The effects of STS AT overexpression in male mice were mediated through 
androgen pathway. 
(A-E) Mice are the same as described in Fig. 2. Shown are adipose expression of estrogen 
responsive genes (A) adipose levels of estrogens (B), adipose expression of androgen responsive 
genes (C), adipose and liver levels of testosterone (D), the serum levels of testosterone (E). (F-M) 
Male mice were castrated before being fed with HFD for 20 weeks. Shown are body weight and 
body composition (F), oxygen consumption (G), GTT and ITT (H), immunostaining of CD68 (I), 
adipose expression of pro-inflammatory genes and macrophage marker genes (J), and adipose 
expression of androgen responsive genes (K). (L and M), Shown are the expression of androgen 
responsive genes in the liver (A) and skeletal muscle (B). Results are expressed as mean ± SD. 
n=4 mice per group. *, P< 0.05; **, P<0.01; ***, P<0.005, compared to the Wt 
4.2.5 AT over-expression of STS ameliorated HFD- induced obesity, insulin resistance, 
glucose tolerance and inflammation in female mice. 
Interestingly, the adipose STS transgenic effect was sex specific, because the phenotypes 
in Tg females were totally opposite to those observed in Tg males. Specifically, the Tg females 
showed a reduced body weight gain, which was due to reduced fat mass (Fig. 13A). The mass of 
perigonidal adipose tissue (peri-WAT), but not the subcutaneous WAT, was decreased in Tg 
females (Fig. 13B). The food intake was not affected by the transgene (Fig. 13C). The oxygen 
consumption in the dark phase was significantly increased (Fig. 13D). The Tg females also showed 
a significantly lower fasting glucose level and better performance in GTT (Fig. 13E) and ITT (Fig. 
13F). The peri-WAT levels of phosphorylated Irs-1 and Akt were increased in the Tg females (Fig. 
13G), further suggesting an improved insulin sensitivity. Histological analysis of the pancreas 
showed no difference in total islet area and islet size (Fig. 13H). The Tg females also showed a 
reduced serum level of triglycerides (Fig. 13H), but no change in the serum cholesterol (Fig. 13I). 
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Opposite to that of male Tg mice, the serum free fatty acid level was increased in female Tg mice 
(Fig. 13J). 
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Figure 13 AT Over-expression of STS alleviated HFD-induced obesity and improved 
insulin sensitivity. 
All mice are females. Mice were fed with HFD for 20 weeks before analysis. (A-F) Mice 
were analyzed for body weight and body composition (A), fat mass (B), food intake (C), oxygen 
consumption (D), GTT (E) and ITT (F). The quantifications of the GTT and ITT results are shown 
as the areas under the curve. (G) Western blot analysis of Irs-1 and Akt phosphorylation in epi-
WAT. Shown on the right are the densitometric quantifications of the Western blotting results. (H 
and I) The serum levels of triglycerides (H) and total cholesterol (I). (J) Shown are H&E staining 
of pancreatic sections and the Image J quantifications of pancreatic islets areas. Results are 
expressed as mean ± SD. n=4 mice per group. *, P<0.05; **, P<0.01, compared to the Wt. 
 
4.2.6 AT over-expression of STS increased energy uptake, AT adipogenesis and 
ameliorated HFD- induced adiposity and systemic inflammation in females. 
Tg females showed increased expression of glucose uptake transporter Glut4 and 
uncoupling proteins in the peri-WAT (Fig. 14A). The expression of adipogenic genes was 
increased in the peri-WAT of Tg females (Fig. 14B), opposite to the suppression in the Tg males. 
The induction of PPARγ was confirmed at the protein level by Western blotting (Fig. 14C). Both 
the peri-WAT expression (Fig. 14D) and circulating level of adiponectin (Fig. 14E) were elevated 
in the Tg females. Consistent with improved metabolic functions and insulin resistance, Tg females 
showed attenuated HFD-induced adipose and systemic inflammation, as evidenced by decreased 
crow-like structures (Fig. 14F), decreased expression of pro-inflammatory genes (Fig. 14G), and 
a decreased circulating level of Il-6 (Fig. 14H).  
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Figure 14 AT over-expression of STS increased energy uptake, AT adipogenesis and 
ameliorated HFD- induced adipose and systemic inflammation in females. 
Mice are the same as described in Fig. 13. (A and B) Adipose expression of genes 
responsible for energy uptake and expenditure (A), and lipogenesis and adipogenesis (B) was 
measured by real-time PCR. (C) The protein level of PPARγ was measured by Western blotting. 
(D and E) The adipose mRNA expression of adiponectin (D) and the serum level of adiponectin 
(E). (F) Immunostaining of Cd68. Shown below is the quantification. (G and H) Adipose 
expression of pro-inflammatory genes and macrophage marker genes (G), and the serum level of 
Il-6 (H). Results are expressed as mean ± SD. n=4 mice per group. *, P<0.05; **, P<0.01, 
compared to the Wt.  
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4.2.7 The metabolic benefit of female AS mice was estrogen-dependent.  
In understanding the metabolic benefit in the Tg females, we found the expression of 
estrogen responsive genes (Fig. 15A), but not the androgen responsive gene (Fig. 15B), was 
induced in the peri-WAT. To further determine whether the metabolic benefit was estrogen 
dependent, we eliminated the primary source of endogenous estrogens from 4-week-old pre-
pubertal female mice by ovariectomy before challenging them with HFD for 20 weeks. Upon 
overiectomy, the expression of estrogen responsive genes in the per-WAT of Tg females no longer 
showed changes (Fig. 15C), whereas the expression of the STS transgene was not affected (data 
not shown). Ovariectomy completely abolished the metabolic benefit of the STS transgene in body 
weight and body composition (Fig. 15D), oxygen consumption (Fig. 15E), GTT and ITT (Fig. 
15F), adipose inflammation at the histological (Fig. 15G) and inflammatory gene expression levels 
(Fig. 15H), and the expression of adipogenic genes (Fig. 15I). Taken together, these data showed 
that the STS effects in female adipose tissue is mediated through estrogen signaling pathway.  
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Figure 15 The effects of STS AT overexpression in female mice were mediated through 
estrogen pathway.  
(A and B) Mice are the same as described in Fig. 5. Shown are adipose expression of 
estrogen responsive genes (A) and androgen responsive genes (B) as measured by real-time PCR. 
(C to I) Female mice were ovariectomized before being fed with HFD for 20 weeks. Shown are 
adipose expression of estrogen responsive genes (C), body weight and body composition analysis 
(D), oxygen consumption (E), GTT and ITT (F), immunostaining of CD68 (G), adipose expression 
of pro-inflammatory genes and macrophage marker genes (H), and genes involved in adipogenesis 
and lipogenesis (I). Results are expressed as mean ± SD. n=4 mice per group. *, P<0.05; **, 
P<0.01, compared to the Wt. 
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4.3 DISCUSSION 
In this study, we reported the adipose induction of Sts in mouse models of obesity and 
insulin resistance. Based on our results, the adipose induction of Sts in response to metabolic stress 
appears to have a sex-specific outcome: it may represent a protective response in females because 
of increased estrogen activity in the adipose tissue; whereas in males, the induction may have 
exacerbated the metabolic harm in an androgen- and inflammation-dependent manner. Under the 
control of the aP2 gene promoter, the STS transgene had the most obvious effect in epi-WAT, 
whereas the subcutaneous WAT and brown adipose tissue showed little appreciable microscopic 
and functional phenotypes although the transgene was efficiently expressed in these two fat depots 
(data not shown). The fat depot specific effect of the STS transgene remains to be understood. 
 
One of the most interesting observations is the sex-dimorphic effect of STS in the adipose 
tissue. Sex dimorphisms have been documented in many aspects of the metabolic syndrome, 
ranging from fat distribution to sex hormone levels. We found that overexpression of STS in the 
adipose tissue of male mice aggravated HFD-induced obesity, insulin resistance and inflammation. 
The worsened metabolic functions in the Tg males were likely resulted from induced androgen 
reactivation and increased androgenic activity in the adipose tissue, whereas castration abolished 
these adverse effects. These results underscored the importance of adipose androgen signaling in 
energy homeostasis. It has been suggested that aromatization of testosterone into estrogens is 
critical to energy homeostasis in males. However, our results showed the STS transgene had little 
effect on the adipose expression of estrogen responsive genes and adipose tissue levels of estrogens 
in Tg males, indicating that the phenotype was specifically caused by increased androgen 
signaling. The HFD-fed Tg females, on the other hand, exhibited improved metabolic functions 
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that included the relief of insulin resistance and adipose inflammation. The metabolic benefit of 
STS in female mice was estrogen dependent, because the responsive genes of estrogens but not 
androgens were induced in the adipose tissue. Moreover, overiectamy abolished the metabolic 
benefit of the STS transgene, further suggesting that estrogens have mediated the metabolic benefit 
in Tg females.  
 
Another interesting finding is the sex hormone dependence of the phenotype. The primary 
function of the STS enzyme is to convert androgen sulfates and estrogen sulfates to hormonally 
active androgens and estrogens. By prediction, the androgen and estrogen levels should be 
increased in the adipose tissue of the Tg mice. Our previously work has largely focused on the the 
role of STS in estrogen conversion. For example, liver-specific transgenic expression of STS 
enhanced estrogen activity and conferred the metabolic benefits in female Tg mice (72). In human 
livers and human liver cells, chronic inflammation activates NF-B and induces the expression of 
STS, which was reasoned to be a major contributor for the estrogen excess in male patients of 
chronic inflammatory liver diseases (105). To our knowledge, the current work represents the first 
study focusing on the role of STS in androgen conversion. Generally, androgens are believed to 
play opposite roles in energy homeostasis in males and females. It has been reported that deficiency 
of androgen worsens metabolic functions in males, while androgen excess worsens metabolic 
functions in females (1). In males, the impact of testosterone deficiency on the development of 
visceral obesity, insulin resistance and metabolic syndrome in men has also been reported (28-30). 
Androgens are known to confer metabolic benefits in many tissues in males, including the liver, 
pancreatic β-cells, and skeletal muscle. For adipose tissue, there is an inverse correlation between 
total serum testosterone and the amount of visceral adipose tissue (48). On one hand, this could be 
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explained by the coverstion of androgens into estrogens by aromatase to provide estrogens for 
tissue metabolism. Indeed, orchidectomized male rodents treated with either testosterone or 
estrogen remain lean, while those treated with the pure androgen DHT that cannot be converted to 
esteogen develop obesity (106). This is also true in men for whom testosterone replacement 
suppresses adiposity, and this effect is blocked in the presence of an aromatase inhibitor (107). On 
the other hand, most of the reported effects of androgens on adipose tissue in males were believed 
to be indirectly mediated by AR signaling in the skeletal muscle (42-44). One of a few studies 
focusing on the specific role of androgens in adipose tissue is using adipocyte-specific androgen 
receptor knockout mice, in which these mice showed no difference in subcutaneous and 
epididymal fat mass in either chow fed condition or HFD condition (48). Furthermore, AR 
regulates adiponectin production. The serum adiponectin levels are high in hypogonadal men and 
are reduced by testosterone therapy (108). Testosterone infusion also decreases the level of 
adiponectin (109), an adipokine that enhances insulin sensitivity (110), reduces chronic 
inflammation and maintains healthy adipose tissue expansion while rescuing ectopic lipid 
accumulation in animal models (111). Consistent with the above finding, the adipose expression 
of adiponectin and the circulating level of adiponectin were decreased in the Tg males, which may 
have contributed to the metabolic harm of the transgene in this sex. Androgens are known for their 
anti-adipogenic activity (112), which may have helped to explain the decreased expression of 
adipogenic genes in the adipose tissue of the Tg males. Taken together, our results have 
demonstrated direct effects of STS and androgens on the adipose tissue of males.  
 
It is also interesting to note that the sex-dimorphic effect of STS is also tissue specific. We have 
previously reported that overexpression of STS in the liver of transgenic mice alleviated HFD and 
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ob/ob models of obesity and type 2 diabetes in both sexes (62). Interestingly, although the 
metabolic benefits of hepatic STS was conserved in both sexes, it appeared that STS exerted its 
metabolic benefit through sex-specific mechanisms. In female mice, STS may have increased 
hepatic estrogen activity by converting estrogen sulfates to active estrogens and consequently 
improved the metabolic functions; whereas ovariectomy abolished this protective effect. In 
contrast, the metabolic benefit of hepatic STS in males may have been accounted for by the male-
specific decrease of inflammation in white adipose tissue and skeletal muscle, as well as a pattern 
of skeletal muscle gene expression that favors energy expenditure. The metabolic benefit of the 
hepatic STS in male mice was intact upon castration. A few notable differences between the 
adipose STS and hepatic STS Tg mice include: 1) The adipose STS was protective in females but 
sensitized males to metabolic stress, whereas the hepatic STS was protective in both sexes; 2) 
Within the male sex, the sensitizing effect of adipose STS was androgen dependent, whereas the 
protective effect hepatic STS remains to be defined, because the protective effect was intact upon 
castration; and 3) Also within the male sex, the adipose STS exacerbated adipose inflammation, 
whereas the hepatic STS attenuated adipose inflammation.  
 
Interesting, the metabolic effect of the estrogen sulfotransferase (EST) is also tissue- and 
sex-specific. EST sulfonates estrogens and convert them to hormonally inactive estrogen sulfates. 
We have previously reported that the induction of hepatic Est is a common feature of several mouse 
models of type 2 diabetes. Loss of Est in female mice improved metabolic function in ob/ob mice 
as a result of decreased estrogen deprivation and increased estrogenic activity in the liver. 
Interestingly, the effect of Est ablation was sex-specific, as Est ablation in ob/ob males exacerbated 
the diabetic phenotype, which was accounted for by increased inflammation in the white adipose 
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tissue, as well as decreased islet β cell mass and failure of glucose-stimulated insulin secretion 
(113). Interestingly, although the diabetes induction of Est was liver specific, transgenic 
reconstitution of EST in the adipose tissue, but not in the liver, attenuated diabetic phenotype in 
male ob/ob mice deficient of Est (114). The metabolic benefit of adipose reconstitution of Est was 
sex-specific, because adipose reconstitution of Est in female ob/ob mice deficient of Est had little 
effect (114). 
 
In summary, this study uncovered a sex-dimorphic and sex hormone-dependent role of STS 
in adipose inflammation and energy homeostasis. The adipose STS may represent a novel 
therapeutic target for the management of obesity and type 2 diabetes. 
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Picture 3 Overview of sex- and adipose tissue specific roles of STS in WAT energy 
homeostasis. 
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 CHAPTER V: SUMMARY AND PERSPECTIVE 
In summary, my thesis points out the importance of sulfotransferase and sulfatase in energy 
homeostasis. Sult2B1b, as cholesterol sulfotansferase inhibits HNF4α mediated gluconeogenesis. 
It also confers an endogenous mechanism with HNF4α to inhibit gluconeogenesis. Blood glucose 
level is mainly regulated by the glucose uptake by the peripheral tissues and the glucose production 
mostly by the liver (10). Gluconeogenesis is the most essential component to contribute to hepatic 
glucose production. Therefore, regulating hepatic gluconeogenesis is very essential to regulate 
whole body blood glucose level (10). Especially, in diabetic condition, increased fasting blood 
glucose level is mostly led by uncontrolled hepatic gluconeogenesis. We found that in fasting stage, 
the expression level of both Sult2B1b and HNF4α was induced, and SultB1b-/- mice showed higher 
fasting blood glucose level. This highly suggests that ablation of Sult2B1b breaking the negative 
feedback regulation between HNF4α and Sult2B1b would increase blood glucose production and 
lead to fasting hyperglycemia. On the other hand, this indicates the importance of the restrictive 
effect of the regulation between HNF4α and Sult2B1b, particularly in diabetic stage. 
 
Our study also demonstrated that Sult2B1b enzymatic product CS and its chemical 
derivative Thiocholesterol could be important component in this negative feedback regulation to 
inhibit gluconeogenesis. The level of CS in the feces of SultB1b-/- mice did decrease associated 
with an increased fasting blood glucose level (data not shown). Thiocholesterol and CS also 
showed significant inhibitive role in hepatic glucose production in primary hepatocytes. When 
treat obese mice with these two chemicals, both of them contents high effectiveness in improving 
whole body glucose homeostasis, insulin resistance and liver steatosis. Moreover, thiocholestol as 
 70 
a synthesized chemical is hydrolysis resistant and more potential to decrease hepatic blood 
production and improve the diabetic phenotypes.   Considering the potential of thiochloesterol as 
a therapeutic drug to manage diabetes and obesity, further preclinical study will be followed. 
 
In addition to the liver, HNF4α and SULT2B1b is also expressed in other tissues for 
example pancreas and adrenal gland (5, 6). Further study will focus on the effect of HNF4α and 
Sult2B1b in other gluconeogenic tissues.  Also, both HNF4α and Sult2B1b are involved in many 
other biological functions, further study may investigate the role this endogenous negative 
feedback regulation in other physiological or pathophysiological conditions.  
 
My thesis study also demonstrated STS as a steroid sulfatase to regulated adipose tissue 
energy homeostasis. One interesting finding was that, STS in male mice decreased adipogenesis 
while in female mice increase adipogenesis, which was dependent on the androgen and estrogen 
signaling pathway respectively. Our previously study published that estrogen sulfotransferase EST 
could influence adipogenesis in adipocyte in a species-specific manner (114). Further study of STS 
may focus on investigating its adipogenic effect in primary adipocyte. Other interesting finding is 
that, STS also influence the thermogenic Ucp1 gene expression. Furthermore, energy expenditure 
of both male and female Tg mice were influenced by STS transgene. This pointed out another 
potential direction to study STS function in beige cell, which is a specific “adipocyte” in white 
adipose tissue, where Ucp1 is highly expressed regulating uncoupling ATP expenditure (115).  
 
As the key enzyme to locally synthesize estrogen, STS has been found to play pathogenic 
role in hormone dependent cancers. It has been decades that researchers investigate STS inhibitors 
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to use as an anti-tumor drug (116).  In this study, I demonstrated that STS in adipose tissue 
aggravated the HFD induced diabetic phenotypes in males and improve those in female mice. 
Therefore, inactivation of STS in males and activation in females could be potential therapeutic 
method to manage the metabolic disorders. Further study could continue to study the effect of STS 
substrate or the available inhibitors in energy homeostasis.  
 
In a conclusion, I demonstrated Sult2B1b and STS though regulating the chemical and 
functional homeostasis of endogenous molecules, for example cholesterol and steroid hormones 
act significant role in energy homeostasis. Both of these enzymes could be potential therapeutic 
target for the management of metabolic syndromes.  
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